Psychoactive Substances Bill [Lords]

Debate between Cheryl Gillan and Dan Poulter

Wednesday 20th January 2016 Commons Chamber

[Dr Poulter]

My hon. Friend is right.

I shall speak, first, about the barriers to mental health research—we know that the use of cannabis has links with mental illness, particularly psychosis—and also about the broader research into the potential medicinal benefits of the many products contained in the cannabis plant. That has been investigated in the United States, where more than 20 states have relaxed their laws to allow the medicinal use of cannabis and cannabis derivatives. I am pleased to hear that the all-party group is to look into that because it is important that we examine the evidence that is out there and, if necessary, consider using that evidence to change the law. The law should be for public protection but also for public benefit, and if there is a legitimate medicinal use of cannabis, we should support and encourage it because that is good for patients.

Before I proceed, I want to touch on the very brave speech from my hon. Friend the Member for Reigate (Crispin Blunt). It is rare that we discuss our personal experiences in the Chamber, but it brings into focus the importance of making sure that the laws that we pass impact positively on the real world and the day-to-day lives of our constituents. He spoke bravely about his own use of poppers, which helped to bring the debate alive and crystallised the importance of that evidence-based policy making. I know the Minister will respond to that later.

On the rescheduling of cannabis from a schedule 1 to a schedule 2 drug, as we are aware, the scheduling of drugs was laid down in the Misuse of Drugs Regulations 2001. The reason that cannabis was considered a schedule 1 drug was that it did not have any medicinal benefit. That is now a matter of considerable contention in the light of the evidence I am about to present. It is important to highlight some of the inconsistencies in legislation.

Under the Schengen agreement, it is legal for somebody in a Schengen country to bring into the UK cannabis for medicinal use, if they have been prescribed it by a doctor on their own country, for up to 30 days, yet it is not legal in this country for a doctor to prescribe cannabis for medicinal purposes unless it happens to be for the purpose of treating multiple sclerosis. That is the one licensed drug currently available. If we recognise that cannabis can be licensed for the treatment of MS, currently under very elaborate licensing law by the Home Office, surely we recognise that there is a medicinal benefit. Quod erat demonstrandum: schedule 1 is the wrong place for cannabis because we accept that it has a medicinal benefit. The Home Office accepts for its licensing programme that there is a medicinal benefit to cannabis, so we need to consider rescheduling the drug.

I have touched on the intervention from my hon. Friend the Member for Winchester (Steve Brine) by reference to the growing evidence from the United States that there are other potential medicinal benefits of cannabis for the treatment of patients. The relaxing of laws in over 20 states on the basis of that evidence is something that we clearly need to look at in this country. In particular, the potential benefits of cannabis products in palliative care merit greater scrutiny. There is inconsistency in the classification of cannabis, which is why I tabled the amendment.

I want to speak about some of the barriers to research. I am very grateful to my right hon. Friend the Minister for Policing, Crime and Criminal Justice for meeting Professor Sir Robin Murray—he is an eminent professor—and Dr Marta Di Forti, who work in mental health, particularly in psychosis, to examine the issue and learn at first hand about some of the difficulties they experience in conducting research into mental ill health. We know that there are links between psychosis and cannabis use, and it is particularly important that we understand the basis on which the plant works on neurotransmitters and that we support researchers in conducting their research. At the moment, those researchers could potentially be criminalised for carrying out research that would be legitimate in many other fields of medical research. I am sure that that is not an intended consequence. It also makes it very difficult to carry out research effectively in the field of mental health and the links with cannabis. I know that the Minister is sympathetic to that and I look forward to hearing how we can find a workable solution to the problem. We want to improve our treatment of patients with mental ill health, but to do that we need properly to support the researchers in carrying out their work, and I hope that the whole House can sign up to that.

This is not an easy matter and it is not part of a broader discussion on the merits or demerits of legalising cannabis. I specifically wanted to table the amendment for discussion today to highlight the difficulties faced by researchers carrying out their jobs and to highlight some of the clear inconsistencies in drug laws in relation to cannabis and, more importantly, drugs that we would consider much more potentially harmful if used by the public. Heroin, or diamorphine, is a schedule 2 drug, whereas cannabis, the use of which is shown by a growing body of evidence to have a medicinal benefit, is a schedule 1 drug. I believe that the Government need to look into the inconsistency in current drug laws, but in particular I would be very grateful for my right hon. Friend the Minister’s comments on how we can facilitate and ease the process of legitimate research without criminalising researchers.

[Mrs Gillan]

Does my hon. Friend also agree that there is a real anomaly when a drug such as DNP, which has caused the death of so many young people and is taken as a drug for body building or to improve people’s perception of their body image, is so classified and falls between so many stools that it is impossible to get it banned, despite the deaths and damage it has caused?

[Dr Poulter]

My right hon. Friend speaks wisely. On that subject, looking at the scheduling, steroids come under schedule 4 to the misuse of drugs regulations. They are often a drug misused by body builders and other athletes whereas, in the example I just gave, diamorphine, or heroin, is a schedule 2 drug. There is now a clear and compelling case, because of the growing medical evidence and the barriers to research, to consider the scheduling of cannabis. More broadly, before we even get to that point, I know that there is more we can do to make it easier to research the links between cannabis and mental health and to support that very important research so that, hopefully, we can move towards a better position through this Bill, not just in protecting the public from psychoactive substances but in improving the care of a number of the most vulnerable patients looked after by our health service.

I intend the amendment as a probing amendment and do not wish to press it to a vote, but I look forward to hearing my right hon. Friend the Minister’s response.

Oral Answers to Questions

Debate between Cheryl Gillan and Dan Poulter

Tuesday 13th January 2015 Commons Chamber

[Mrs Cheryl Gillan (Chesham and Amersham) (Con)]

Last month, I contacted one of my excellent GPs in Chesham concerning the waiting time for one of my constituents. In his response, he reminded me that Buckinghamshire patients receive less funding per head than almost anywhere in the country. What can be done to address that inequality, so that my constituents can benefit from the same level of funding for services and treatment enjoyed by other parts of the country?

[Dr Poulter]

As my right hon. Friend will be aware, the funding formula is now reviewed regularly. That is done independently and is free from political interference. Looking at areas such as hers, where there are a lot of frail and elderly patients, is now more paramount in the funding formula. In the future, I am sure that the funding formula will better reflect local health care needs.